Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution

Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis

(2018) R. Gniadecki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Real-world use of apremilast for patients with psoriasis in Japan

(2018) Megumi Kishimoto et al.   JOURNAL OF DERMATOLOGY

Switching of biologics in psoriasis: Reasons and results

(2017) Hiromi Honda et al.   JOURNAL OF DERMATOLOGY

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial

(2017) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Switching biologics in the treatment of psoriatic arthritis

(2017) Joseph F. Merola et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

(2016) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study

(2016) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis

(2016) Ai Matsumoto et al.   JOURNAL OF DERMATOLOGY

Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

(2015) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

(2015) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis

(2015) Alexander Nast et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis

(2015) Wolf-Henning Boehncke et al.   LANCET

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2013) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study

(2013) Vito Di Lernia et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

(2012) C. Leonardi et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

(2011) Vito Di Lernia et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

(2011) Roberto Perez-Alvarez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

(2007) Lily Clark et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY